Biallelic loss, loss of heterozygosity, point mutations and epigenetic silencing of the B2M gene that result in MHC-I deficiency are frequently encountered across several human cancers and are thought to be contributory to ICI resistance(10–14). This evidence concerns the gene B2M and cancer.